Literature DB >> 1159084

Complete absence of the third component of complement in man.

M Ballow, J E Shira, L Harden, S Y Yang, N K Day.   

Abstract

A 4-yr-old female patient who has recurrent infections with encapsulated bacteria and gramnegative organisms was found to have a complete absence of total hemolytic complement and C3. Total hemolytic complement was reconstituted by the addition of functionally pure C3. With the exception of a moderately reduced homolytic C4, all other C components, measured homolytically and by radial immunodiffusion, were present in normal amounts. By Ouchterlong analysis, the patient's serum contained C3b inactivator and properdin but no antigenic C3. Activation of the alternate pathway was examined by purified cobra venom factor (CVF) and inulin. Neither of these substances led to activation of properdin factor B to B. On addition of partially purified Cordis C3, in four out of four instances and with different preparations of Cordis C3, activation of factor B to B occurred in the inulin-serum-C3 mixture. In contrast, activation of factor B to B occurred only once out of four times with CVF-serum-C3 mixtures. Immune adherence was found to be normal in the patient's serum and could be removed by anti-C4 antiserum of hydrazine treatment. A marked opsonic defect was present against Escherichia coli. Serum bactericidal activity against a rough strain of E. coli was also defective. The ability to mobilize an infalmmatory response was examined by Rebuck skin window technique. A delay in neutrophil migration occurred until the 6th h. In vitro lymphocyte transformation and serum immunoglobulins were normal. The proportion of peripheral blood T cells forming spontaneous sheep erythrocyte rosettes and the percentage of B cells forming EAC rosettes by the C3 receptor were normal. The significance of the absence of C3 in our patient is emphasized by the increased number of infections with encapsulated bacteria and the decreased functional biological activities of the C system, important in host defense mechanism(s).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159084      PMCID: PMC301919          DOI: 10.1172/JCI108141

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Measurements of complement by agglutination of human erythrocytes reacting in immune-adherence.

Authors:  K NISHIOKA
Journal:  J Immunol       Date:  1963-01       Impact factor: 5.422

2.  A method of studying leukocytic functions in vivo.

Authors:  J W REBUCK; J H CROWLEY
Journal:  Ann N Y Acad Sci       Date:  1955-03-24       Impact factor: 5.691

3.  Quantitative studies on the bactericidal actions of serum and complement. I. A rapid photometric growth assay for bactericidal activity.

Authors:  L H MUSCHEL; H P TREFFERS
Journal:  J Immunol       Date:  1956-01       Impact factor: 5.422

4.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

5.  The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.

Authors:  R A NELSON
Journal:  Science       Date:  1953-12-18       Impact factor: 47.728

6.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.

Authors:  O Götze; H J Müller-Eberhard
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

7.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

8.  Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies.

Authors:  J P Leddy; M M Frank; T Gaither; J Baum; M R Klemperer
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  21 in total

1.  Homozygous hereditary C3 deficiency due to a premature stop codon.

Authors:  Edimara Da Silva Reis; Gisele Vanessa Baracho; Adriana Sousa Lima; Chuck S Farah; Lourdes Isaac
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

2.  The effect of complement depletion on lung clearance of bacteria.

Authors:  G N Gross; S R Rehm; A K Pierce
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

3.  Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.

Authors:  S I Rosenfeld; M E Kelly; J P Leddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

4.  Defective release of C5a related chemo-attractant activity from complement in Crohn's disease.

Authors:  J Elmgreen; A Berkowicz; H Sørensen
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

5.  A molecular concept of the properdin pathway.

Authors:  R G Medicus; R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

6.  Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.

Authors:  W E Brandeis; L Helson; Y Wang; R A Good; N K Day
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

7.  Inherited deficiency of the seventh component of complement associated with nephritis. Propensity to formation of C56 and related C7-consuming activity.

Authors:  G R Nemerow; H Gewurz; S G Osofsky; T F Lint
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

Review 8.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

9.  Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure.

Authors:  R J Wyke; A G Yousif-Kadaru; I A Rajkovic; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

Review 10.  Clinical conditions associated with defective polymorphonuclear leukocyte chemotaxis.

Authors:  P G Quie; K L Cates
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.